CliffBio
small molecule

METHYLDOPA AND CHLOROTHIAZIDE

CHLOROTHIAZIDE; METHYLDOPA

Loss of exclusivity—loss of exclusivity
CompanyPar →See this company's full patent-cliff portfolio

Drug detail

Brand nameMETHYLDOPA AND CHLOROTHIAZIDE
Active ingredientCHLOROTHIAZIDE; METHYLDOPA
Strength150MG;250MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 1987
Marketing statusDISCN

More from Par

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

METHYLDOPA AND CHLOROTHIAZIDE patent cliff — loss of exclusivity — | CliffBio